JPMorgan reinstated coverage of Nektar with an Underweight rating and no price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NKTR: